相关实验视频
Updated: May 8, 2026

11:10
Hyperinsulinemic-euglycemic Clamps in Conscious, Unrestrained Mice
Published on: November 16, 2011
肥胖的超血症 - - 调节热量余的调节者
1Touchstone Center for Diabetes Research, Department of Internal Medicine, UT Southwestern Medical Center at Dallas, 5323 Harry Hines Boulevard, Y8.212, Dallas, TX 75390, USA.
Cell
|April 16, 2004
概括
莱普和厌食药物通过非活性化下丘脑AMP激活蛋白激酶 (AMPK) 来降低食欲,从而增加马洛尼尔CoA. 这项研究探讨了AMP生物学,马洛尼尔-CoA生成和丁.
科学领域:
- 神经科学是一个神经科学.
- 代谢调节 代谢调节 代谢调节
- 肥胖问题研究研究
背景情况:
- 素是调节能量平衡和食欲的关键激素.
- 低垂体AMP激活蛋白激酶 (AMPK) 在食欲控制中起着至关重要的作用.
- 马洛尼尔CoA是脂肪酸合成中的中间体,也是能量代谢的调节者.
研究的目的:
- 检查AMP生物学在马洛尼尔-CoA生成中的作用.
- 整合AMPK的中心作用与其外围作用在莱普生理学中的作用.
- 了解瘦素和相关药物降低肥胖症食欲的机制.
主要方法:
- 对AMP生物学,马洛尼尔-CoA代谢和瘦素信号传递现有文献的审查.
- 分析AMPK的中心和外围行动之间的相互作用.
- 在肥胖和食欲调节的背景下整合发现.
主要成果:
- 有证据表明,丁会使下丘脑AMPK失活,导致马洛尼尔CoA水平升高.
- 厌食原剂对AMPK的不活化有助于抑制食欲.
- 在食欲控制中AMPK的核心作用与其外周抗脂质毒性功能有关.
结论:
- 莱普降低食欲的作用,部分是通过下丘脑AMPK的失活来调解的.
- 了解AMPK的中心和外围作用对于理解叶黄素在肥胖中的作用至关重要.
- 这项工作为研究针对AMPK-马洛尼尔CoA途径用于肥胖管理的新型治疗策略提供了框架.
相关概念视频
Regulation of Food Intake
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
Obesity
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in adipocytes...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
Hypoglycemia
Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
Hyperglycemia
Hyperglycemia is an abnormally high blood glucose level. It is diagnosed by fasting glucose ≥126 mg/dL, 2-hour oral glucose tolerance test (or OGTT) ≥200 mg/dL, random glucose ≥200 mg/dL with symptoms, or HbA1c ≥6.5%. However, HbA1c results may be unreliable in certain conditions, such as anemia or hemoglobinopathies, and the diagnosis should be confirmed unless classic symptoms are present. Postprandial hyperglycemia is typically considered significant when glucose levels exceed 180 mg/dL two...

